Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
First Claim
Patent Images
1. A purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention is in the field of immunology. More specifically, it relates to compositions and methods for identifying, treating and preventing cancer by targeting the extracellular domains of the frizzled receptor family of proteins.
-
Citations
26 Claims
- 1. A purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell.
- 11. An isolated nucleic acid, comprising at least one nucleotide fragment encoding a peptide having an amino acid sequence that is greater than 80% homologous to an amino acid sequence selected from the group Seq. ID No.s 61, 63, 64, 66, 68, 69, 71, 73, 75 and 77.
-
16. A pharmaceutical composition comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier.
-
17. A method for modulating a biological activity of a malignant cell that expresses a frizzled receptor comprising administering a pharmaceutical composition comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier.
- 18. A frizzled receptor epitope conjugate comprising at least one epitope in an extracellular domain of the frizzle receptor expressed on a malignant cell and at least one epitope specific to a T cell antigen.
-
22. A pharmaceutical composition useful as a vaccine against malignancy for administration to a patient having a predisposition for the malignancy, comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell.
-
23. A method of immunizing a subject against a malignancy comprised of malignant cells that express a frizzled receptor, said method comprising the steps of:
-
a) identifying an antibody for modulating a biological activity of the malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell; and
b) administering the antibody in a pharmaceutically acceptable carrier in an amount sufficient to inhibit the malignancy.
-
-
24. A method of treating a subject with a malignancy comprised of malignant cells that express a frizzled receptor, said method comprising the steps of:
- ;
a) identifying an antibody for modulating a biological activity of the malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell; and
b) administering the antibody in a pharmaceutically acceptable carrier in an amount sufficient to modulate a biological activity of the malignant cell.
- ;
-
25. An assay for identifying a frizzled receptor expressed by a malignant cell, wherein said frizzled receptor comprises at least one epitope in an extracellular domain, comprising the steps of:
-
a) identifying an antibody that specifically binds to the epitope;
b) exposing a sample of cells suspected of expressing the frizzled receptor to the antibody; and
c) determining the extent of binding of the antibody to the cells.
-
-
26. A screening assay for identification of small molecules that modulate frizzled receptor activity, comprising:
-
a) selecting a library of the small molecules comprising a plurality of different chemical structures;
b) contacting the small moleucles with an extracellular domain of a frizzled receptor which is capable of binding to its corresponding Wnt protein; and
c) measuring binding of a ligand to the frizzled receptor in the presence of the small molecule, wherein the ligand is selected from the group consisting of the small molecule, the Wnt protein, and an antibody to the extracellular domain of the frizzled receptor.
-
Specification